Acrux Limited · ASX:ACR
Acrux — Investor Presentation (August 2020)
20 slides from Acrux's investor presentation, Aug 25, 2020
Slide 1: Acrux Investor Presentation
For personal use only ACRUX INVESTOR PRESENTATION (ASX: ACR) August 2020
Slide 2: Important Notice and Disclaimers
IMPORTANT NOTICE AND DISCLAIMERS For personal use only This presentation contains forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based
Slide 3: Key Investment Highlights
KEY INVESTMENT HIGHLIGHTS Acrux is a revenue generating pharmaceutical company with an extensive product pipeline of For personal use only topical generic pharmaceuticals nearing additional regulatory and commercialisation milestones ▪ 2 products on market in 35 countries Focus on ▪ The topical gene
Slide 4: Acrux History
ACRUX HISTORY • Acrux has over 20 years of experience in the development and commercialisation of topical and For personal use only transdermal pharmaceuticals • Acrux products are currently sold in 35 countries European Union launch for estradiol spray First US FDA Three commercial US FDA Approval
Slide 5: Experienced Management Team with a Proven History of Commercialising Generic Drugs
EXPERIENCED MANAGEMENT TEAM WITH A PROVEN HISTORY OF COMMERCIALISING GENERIC DRUGS CEO & MD Michael Kotsanis leads a team of highly credentialed experts in generic drugs For personal use only Michael Kotsanis BSc, MBus Felicia Colagrande, BSc(Hons), MBA Product Development and Technical Affairs Dire
Slide 6: Strategic Direction Led by a Board with Highly Relevant Expertise
STRATEGIC DIRECTION LED BY A BOARD WITH HIGHLY RELEVANT EXPERTISE For personal use only Michael Kotsanis Ross Dobinson CEO & Managing Director Non-Executive Palla • Experienced leader in the pharmaceuticals industry with Chairman Pharma demonstrated success commercialising generic products • Experie
Slide 7: Business Overview
BUSINESS OVERVIEW 1. Acrux is a specialty topical and transdermal drug development and commercialisation company For personal use only 2. Acrux is a revenue generating pharmaceutical company with an extensive product pipeline of topical generic pharmaceuticals creating additional regulatory and comm
Slide 8: Strong and Consistent Returns
STRONG AND CONSISTENT RETURNS Acrux’s diversified drug development strategy provides more certainty than novel drug development For personal use only Acrux’s generic portfolio strategy Novel drug development Portfolio Strategy Single Drug Strategy Commercial Sophisticated screening of generic drug c
Slide 9: Topical Generics: An Attractive US$18B Market
TOPICAL GENERICS: AN ATTRACTIVE US$18B MARKET Acrux focus: For personal use only Total market Oral drugs Topical drugs Definition of market Drugs that are applied topically Total US prescription Drugs that are (all drugs including NCEs (including directly to the skin, eyes, pharma market ingested or
Slide 10: Revenue Generating Business Model Supporting Long-Term Growth
REVENUE GENERATING BUSINESS MODEL SUPPORTING LONG-TERM GROWTH For personal use only 1 2 ▪ On market products are Generic drug Development generating growing royalty and technology identification revenues for Acrux transfer to CMO ▪ Through the Acrux GMP* facility with 25 specialised scientists, Acru
Slide 11: Acrux Product Portfolio
ACRUX PRODUCT PORTFOLIO The Acrux pipeline will add to the commercialised portfolio of products sold For personal use only through the Acrux network of licensees ▪ Evamist® sold by Perrigo in the United States and Lenzetto® sold by Gedeon Richter in the European Union and a number of other countries
Slide 12: Acrux Product Pipeline's $1.3 Billion Addressable Market
ACRUX PRODUCT PIPELINE’S $1.3 BILLION ADDRESSABLE MARKET Acrux’s investment in R&D unlocks a $1.3bn market in topical drugs For personal use only Addressable market value of pipeline1 (US$bn) # of commercialised generic (ANDA) Addressable market competitors approved and on the market2 US$1.3 bn > 4
Slide 13: Acrux Partnered Pipeline Addressable Market
ACRUX PARTNERED PIPELINE ADDRESSABLE MARKET Over US$860 million of addressable market value licensed to TruPharma, Amring Pharmaceuticals and Harris Pharmaceutical in 2020. Profit share payable to Acrux following For personal use only product launches with milestones on selected products pre and pos
Slide 14: Overview of Current Licensees
OVERVIEW OF CURRENT LICENSEES For personal use only • Licensed 6 products to sell • Co-development with • Licensed 1 product to sell in the US when approved Acrux for of 1 product for in the US when approved by the FDA the US market by the FDA • Sells Lenzetto® in 34 • Sells Evamist® in the countrie
Slide 15: Case Study: Sol-Gel's Revenue from its First Generic Product Licensed to Perrigo
CASE STUDY: SOL-GEL’S REVENUE FROM ITS FIRST GENERIC PRODUCT LICENSED TO PERRIGO For personal use only ▪ A small clinical-stage dermatology company focused on identifying, developing and commercialising branded and generic topical drug products ▪ Announced FDA approval for first and currently only g
Slide 16: Platform for Growth Established
PLATFORM FOR GROWTH ESTABLISHED Through investment in the platform over the past 5 years Acrux has a competitive advantage in the identification, development, registration and launch of generic topical drugs For personal use only Acrux Product Status Description Acrux is receiving royalties on a qua
Slide 17: Future Catalysts
FUTURE CATALYSTS For personal use only The success of Acrux’s strategy and management’s execution will be driven and measured by: ACRUX • Commercial launch and cash flow generation from new generic drugs STRATEGY • Licensing and profit share agreements with generic pharmaceutical companies • FDA app
Slide 18: Corporate Overview
CORPORATE OVERVIEW Acrux has a proven track record of commercialising products, and is entering a new phase of value creation for shareholders following 5 years of R&D For personal use only Trading information Share price performance (last 12 months) Share price (as at 21 August 2020) A$0.17 Shares
Slide 19: Benefits of a Pooled Development Fund
BENEFITS OF A POOLED DEVELOPMENT FUND For personal use only 1 Companies with PDF status are taxed at 15% on their income and capital gains received from their investments 2 Australian resident shareholders are exempt from capital gains tax after selling their shares 3 Unfranked dividends received by
Slide 20: Thank You
For personal use only THANK YOU Michael Kotsanis CEO & Managing Director Acrux Limited P: + 61 3 8379 0100 E: michael.kotsanis@acrux.com.au Visit our website: http://www.acrux.com.au/ Follow us on LinkedIn: